Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-Step Allogeneic Transplant for Multiple Myeloma
NCT00003954Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 1999
- Primary completion
- Dec 2002
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of peripheral blood stem cells in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Progression-Free Survival at 3 years, Non-Relapse Mortality at 100 days and 1 more. Started Mar 1999; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00003954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003954.